Sumitomo Mitsui Trust Group Inc. Sells 19,090 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Sumitomo Mitsui Trust Group Inc. decreased its position in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 6.6% during the 3rd quarter, Holdings Channel reports. The fund owned 269,369 shares of the company’s stock after selling 19,090 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in COMPASS Pathways were worth $1,697,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Rosalind Advisors Inc. boosted its stake in COMPASS Pathways by 6.5% during the 3rd quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company’s stock worth $4,923,000 after acquiring an additional 47,423 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in COMPASS Pathways by 34.7% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 148,134 shares of the company’s stock worth $933,000 after acquiring an additional 38,145 shares during the last quarter. Green Alpha Advisors LLC bought a new position in COMPASS Pathways during the 3rd quarter worth approximately $99,000. Logos Global Management LP lifted its stake in COMPASS Pathways by 349.3% in the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock valued at $7,001,000 after buying an additional 901,050 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in COMPASS Pathways by 1,518.4% in the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock valued at $1,593,000 after buying an additional 247,500 shares in the last quarter. Institutional investors own 46.19% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on CMPS shares. Maxim Group cut their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Canaccord Genuity Group cut their price target on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research note on Monday, September 9th. HC Wainwright cut their price target on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Royal Bank of Canada cut their price target on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, COMPASS Pathways presently has an average rating of “Buy” and an average price target of $30.67.

Insider Transactions at COMPASS Pathways

In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the transaction, the insider now directly owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. The trade was a 27.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.25% of the stock is currently owned by insiders.

COMPASS Pathways Stock Performance

Shares of CMPS stock opened at $4.76 on Wednesday. The company’s fifty day simple moving average is $6.05 and its 200-day simple moving average is $6.76. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a market cap of $325.68 million, a PE ratio of -2.16 and a beta of 2.29. COMPASS Pathways plc has a 12 month low of $4.05 and a 12 month high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter in the prior year, the business posted ($0.67) earnings per share. Equities research analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.